52
DRUG İNTERACTİONS Yasar Kucukardali Professor , Internal Medicine Yeditepe University

Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Embed Size (px)

Citation preview

Page 1: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

DRUG İNTERACTİONSYasar Kucukardali Professor , Internal Medicine Yeditepe University

Page 2: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 3: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Drug interactions

Definition;

it is the modification of the effect of one drug (the object drug ) by the prior concomitant administration of another (precipitant drug).

Page 4: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Outcomes of drug interactions

1) Loss of therapeutic effect2) Toxicity3) Unexpected increase in pharmacological activity4) Beneficial effects e.g additive & potentiation (intended)

or antagonism (unintended).5) Chemical or physical interaction

e.g I.V incompatibility in fluid or syringes mixture

Page 5: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

* Risk factors:

1) High risk drugs; these are the drugs that show a narrow therapeutic index e.g., corticosteroids, rifampin, oral contraceptives, quindine, lidoquine

2) High risk patients; these are the groups of patients that should be treated with caution due to a specific heath condition e.g., pregnant women, malignant cases, diabetic patients, patients with liver or kidney disorders asthmatic patients and cardiac disorders.

Page 6: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Drug-drug interactions (DDIs) are an important subgroup of ADEs which are highly prevalent in patients receiving multiple-drug treatment .

DDIs may lead to severe adverse events which can result in patienthospitalization.

Some studies have estimated that up to 3% of hospital admissions are caused by DDIs .

Page 7: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Estimates about the incidence of DDIs in different countries vary from 6% to 70% due to variability in methodologies and settings .

20% of hospitalized patients were susceptible to DDIs

incidence was higher in patients with heart disease, elderly patients and about one-third of cancer patients

Page 8: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 9: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 10: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 11: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 12: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 13: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Mechanisms of Drug Interaction• Pharmacokinetic– Reduced rate and/or completeness of absorption– Altered bioavailabilty– Reduced plasma protein binding– Altered tissue distribution– Altered hepatic metabolism– Altered renal excretion– Haemodynamic interactions

• Pharmacodynamic– Potentiation/antagonism at target receptor– Potentiation at non-target receptor– Alteration of fluid/electrolyte environment– Interference with transport mechanisms

Page 14: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

In reviewing the patient history, consider the following characteristics in

relation to drug pharmacokinetics:Age: Most drugs were studied in adult patients and recommended dosages may vary in different age groups.Sex: Although data are limited, male and female patients can metabolize and eliminate drugs differently, so the optimal drug dosages may differ.Weight: For patients who are obese or cachectic, changes in drug clearance or volume of distribution often necessitate dosage adjustments.

Disease conditions: Three conditions that must be approached with special caution when prescribing any drug are heart failure (HF), renal disease, and hepatic failure. As HF progresses, bodily organ blood flow declines; the ensuing drug clearance decline necessitates lower dosages for many agents. As kidney or liver function declines, the renal and hepatic elimination of drugs decreases, leading to lower dosage requirements for renally and hepatically cleared agents, respectively.

Genetics: Pharmacogenomics is the study of the relationship of genetics in drug metabolism and ADRs. In a systematic review by Phillips and colleagues, of 27 drugs known to frequently cause ADRs, 59% were known to be influenced by individual patient genetic characteristics.

Page 15: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 16: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 17: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 18: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Drugs with low bioavailability due to high pre-systemic metabolism (First

pass effect

Page 19: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 20: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 21: Yasar Kucukardali Professor, Internal Medicine Yeditepe University

Pharmacodynamic MechanismsWhen drugs with similar pharmacologic effects are administered concurrently, an additive or synergistic response is usually seen.

The two drugs may or may not act on the same receptor to produce such effects.

In theory, drugs acting on the same receptor or process are usually additive, eg, benzodiazepines plus barbiturates.

Drugs acting on different receptors or sequential processes may be synergistic, eg, nitrates plus sildenafil or sulfonamides plus trimethoprim.

Conversely, drugs with opposing pharmacologic effects may reduce the response to one or both drugs.

Page 22: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 23: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 24: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 25: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 26: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 27: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 28: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 29: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 30: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 31: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 32: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 33: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 34: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 35: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 36: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 37: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 38: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 39: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 40: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 41: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 42: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 43: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 44: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 45: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 46: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 47: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 48: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 49: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 50: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 51: Yasar Kucukardali Professor, Internal Medicine Yeditepe University
Page 52: Yasar Kucukardali Professor, Internal Medicine Yeditepe University